Mirna’s pipeline consists of eight lead candidates, all of which are directed toward oncology. Extensive experimental testing demonstrated robust anti-tumor activity in multiple animal models of cancer, suggesting that these miRNAs are key tumor suppressors with broad therapeutic potential. Mirna’s target cancers are solid and blood-borne tumors, with a current focus on hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer and pancreatic carcinoma. Mirna filed its first IND in Q1 2013 and is currently conducting a Phase I Clinical Trial in patients with unresectable primary liver cancer or metastatic cancer with liver involvement. Please click here to learn more about this program (MRX34). Mirna’s platform also contains candidates for therapies in other disease areas.